NasdaqCM - Delayed Quote USD

Nektar Therapeutics (NKTR)

0.7964
+0.0719
+(9.92%)
At close: June 2 at 4:00:00 PM EDT
0.7800
-0.02
(-2.06%)
After hours: June 2 at 7:45:16 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
87,248
98,427
90,122
92,055
101,907
Cost of Revenue
22,152
30,686
33,768
21,635
24,897
Gross Profit
65,096
67,741
56,354
70,420
77,010
Operating Expense
204,928
197,659
191,579
310,656
523,113
Operating Income
-139,832
-129,918
-135,225
-240,236
-446,103
Net Non Operating Interest Income Expense
-14,401
-13,612
-6,325
-22,128
-44,582
Other Income Expense
25,501
24,330
-134,706
-102,619
-32,595
Pretax Income
-128,732
-119,200
-276,256
-364,983
-523,280
Tax Provision
-152
-239
-200
3,215
557
Net Income Common Stockholders
-133,041
-118,961
-276,056
-368,198
-523,837
Diluted NI Available to Com Stockholders
-133,041
-118,961
-276,056
-368,198
-523,837
Basic EPS
-0.63
-0.58
-1.45
-1.97
-2.86
Diluted EPS
-0.63
-0.58
-1.45
-1.97
-2.86
Basic Average Shares
209,705.5000
205,661
190,001
187,138
183,298
Diluted Average Shares
209,705.5000
205,661
190,001
187,138
183,298
Total Operating Income as Reported
-114,306
-105,198
-263,684
-376,166
-446,103
Total Expenses
227,080
228,345
225,347
332,291
548,010
Net Income from Continuing & Discontinued Operation
-133,041
-118,961
-276,056
-368,198
-523,837
Normalized Income
-158,536.8602
-143,631.4356
-147,690
-287,220.6300
-517,980.2100
Interest Income
13,154
14,500
19,009
6,783
2,731
Interest Expense
27,555
28,112
25,334
28,911
47,313
Net Interest Income
-14,401
-13,612
-6,325
-22,128
-44,582
EBIT
-101,177
-91,088
-250,922
-336,072
-475,967
EBITDA
-97,967
-86,697
-243,107
-323,042
-461,821
Reconciled Cost of Revenue
22,152
30,686
33,768
21,635
24,897
Reconciled Depreciation
3,210
4,391
7,815
13,030
14,146
Net Income from Continuing Operation Net Minority Interest
-133,041
-118,961
-276,056
-368,198
-523,837
Total Unusual Items Excluding Goodwill
25,526
24,720
-128,459
-102,503
-8,023
Total Unusual Items
25,526
24,720
-128,459
-102,503
-8,023
Normalized EBITDA
-123,493
-111,417
-114,648
-220,539
-453,798
Tax Rate for Calcs
0
0
0
0.0002
0.0003
Tax Effect of Unusual Items
30.1398
49.5644
-93
-21,525.6300
-2,166.2100
12/31/2021 - 5/3/1994

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LXEO Lexeo Therapeutics, Inc.
2.7200
0.00%
 
CRVS Corvus Pharmaceuticals, Inc.
4.0300
+6.61%
 
MREO Mereo BioPharma Group plc
2.5500
+18.60%
 
KYMR Kymera Therapeutics, Inc.
43.13
+45.51%
 
CYTK Cytokinetics, Incorporated
31.21
+0.61%
 
LYEL Lyell Immunopharma, Inc.
8.22
-5.89%
 
SGMO Sangamo Therapeutics, Inc.
0.4729
+1.70%
 
CTMX CytomX Therapeutics, Inc.
2.5100
-5.28%
 
ITOS iTeos Therapeutics, Inc.
10.01
-0.10%
 
JSPR Jasper Therapeutics, Inc.
5.45
-0.91%